Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: Results of two randomized, double-blind, placebo-controlled studies

Richard G. Langley, Kim Papp, Robert Bissonnette, Darryl Toth, Robert Matheson, Micki Hultquist, Barbara White

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: Results of two randomized, double-blind, placebo-controlled studies'. Together they form a unique fingerprint.

Medicine & Life Sciences